Selinexor

Verified

Overview

Selinexor is the first in a new class of drugs being investigated as a treatment for myeloma. It belongs to a class of drug called selective inhibitor of nuclear export (SINE) and works by disrupting survival mechanisms in myeloma cells.

SparkCures ID 128
Developed By Karyopharm Therapeutics
Generic Name Selinexor
Additional Names KPT-330
Treatment Classifications
Tags

Clinical Trials

All Clinical Trials

View all active clinical trials around the US.

Early Relapse Multiple Myeloma

The following is a listing of clinical trials for patients with multiple myeloma who have received one to two prior lines of therapy.

Late Relapse Multiple Myeloma

The following is a listing of clinical trials for patients with multiple myeloma who have received three or more prior lines of therapy.

Smoldering Myeloma
Monoclonal Gammopathy of Undetermined Significance (MGUS)

Resources

SparkCures Verified

SparkCures is working closely with Karyopharm Therapeutics to provide the most up-to-date information on this treatment. Use the button above to add this treatment to your list of favorites.

Learn more about how we work with industry partners